Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02665234
Other study ID # MIM-726
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date January 2016
Est. completion date March 2017

Study information

Verified date August 2019
Source Mimetogen Pharmaceuticals USA, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety and efficacy of Tavilermide Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye disease.


Recruitment information / eligibility

Status Completed
Enrollment 400
Est. completion date March 2017
Est. primary completion date February 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Be at least 18 years of age.

- Provided written informed consent.

- Have a reported history of dry eye Have a history of use or desire to use eye drops for dry eye

Exclusion Criteria:

- Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal) at Visit 1.

- Be diagnosed with ocular rosacea, or any viral or bacterial disease of the cornea or conjunctiva, within the last 12 months.

- Have any planned ocular and/or lid surgeries over the study period.

- Have corrected visual acuity greater than or equal to +0.7 as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at Visit .

- Have an uncontrolled systemic disease.

- Be a woman who is pregnant, nursing or planning a pregnancy.

- Be a woman of childbearing potential who is not using an acceptable means of birth control

- Have a known allergy and/or sensitivity to the test article or its components.

- Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study

- Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 45 days of Visit 1 Be unable or unwilling to follow instructions, including participation in all study assessments and visits

Study Design


Intervention

Drug:
1% Tavilermide Ophthalmic Solution
1% Tavilermide BID Dosing
Placebo Ophthalmic Solution
Vehicle Ophthalmic Solution

Locations

Country Name City State
United States MIM-726 Investigational Site Torrance California

Sponsors (1)

Lead Sponsor Collaborator
Mimetogen Pharmaceuticals USA, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total Corneal Fluorescein Staining Using The Ora Calibra Scale An assessment of the total corneal fluorescein staining using the Ora Calibra Scale both immediately prior to and immediately following exposure to a challenge in a controlled adverse environment (CAE) Day 57
Primary Ocular Discomfort Using The Ora Calibra Scale A patient-reported subjective assessment of ocular discomfort recorded at each of the 5 office visits throughout the treatment period Day 57
Secondary Total Corneal Fluorescein Staining Using The Ora Calibra Scale An assessment of the total corneal fluorescein staining using the Ora Calibra Scale both immediately prior to and immediately following exposure to a challenge in a controlled adverse environment (CAE) Day 15
Secondary Ocular Surface Disease Index Day 57
Secondary Ocular Dryness Using The Ora Calibra Scale A patient-reported subjective assessment of ocular dryness recorded twice daily over the complete treatment period. 8 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05618730 - Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B Phase 1
Completed NCT02254265 - Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca Phase 2/Phase 3
Completed NCT00883649 - Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye N/A
Completed NCT00717418 - Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease N/A
Completed NCT00128245 - Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca Phase 2
Enrolling by invitation NCT03436576 - Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye Phase 3
Completed NCT04147650 - Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome Phase 2/Phase 3
Completed NCT01733992 - A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease Phase 1
Completed NCT00987727 - Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Phase 4
Completed NCT00788229 - Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome Phase 2
Completed NCT00554879 - Acupuncture Treatment of Dry Eye N/A
Completed NCT00407043 - Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Phase 4
Completed NCT00001731 - Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops Phase 2
Recruiting NCT03953703 - Levocarnitine for Dry Eye in Sjogren's Syndrome Phase 2
Withdrawn NCT03398018 - Repository Corticotropin Injection in Keratoconjunctivitis Sicca Phase 4
Recruiting NCT02066896 - Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome Phase 3
Completed NCT02139033 - A Phase 4 Study Investigating the Efficacy of Retaineā„¢ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Phase 4
Terminated NCT01213342 - Omega-3 Fatty Acid Supplements and Dry Eye N/A
Completed NCT00201981 - Study of Rebamipide Eye Drops to Treat Dry Eye Phase 3
Completed NCT00201955 - Study of Rebamipide Eye Drops to Treat Dry Eye Phase 3